C18 Globotriaosylceramide-d3 (d18:1/18:0-d3) (Synonyms: N-ω-CD3-Octadecanoyl-ceramide Trihexoside, Galα1-4Galβ1-4Glcβ-Cer(d18:1/18:0) d3, Gb3(d18:1/18:0-d3), Globotriaosylceramide-d3 (d18:1/18:0-d3)) |
| Katalog-Nr.GC46995 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C18 Globotriaosylceramide-d3 is intended for use as an internal standard for the quantification of C18 globotriaosylceramide by GC- or LC-MS. C18 globotriaosylceramide is an endogenous sphingolipid that accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A.1 [Matreya, LLC. Catalog No. 1537]
1.Kamani, M.A., ProvenÇal, P., Boutin, M., et al.Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletionFuture Sci. OA.2(4)FS0147(2016)
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *